Loading
Shukui Qin has led most of the Chinese liver cancer trials of the past decade, including the ones that put camrelizumab plus rivoceranib and donafenib into first-line use.
Principal investigator of CARES-310 (camrelizumab plus rivoceranib versus sorafenib, Lancet 2023), the donafenib versus sorafenib trial (Journal of Clinical Oncology 2021), apatinib in second-line HCC and many Chinese cohorts of global liver cancer trials; past president of the CSCO and author of its liver cancer guidelines. His trials reflect the hepatitis B-driven Chinese HCC population that differs from Western cohorts.
Shares Rivoceranib (apatinib) and the tag china.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares ZGDH3 (donafenib vs sorafenib), Donafenib and the tag china.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares Hepatocellular carcinoma and the tag china.
Shares Hepatocellular carcinoma and the tag china.
Shares Hepatocellular carcinoma and the tag china.
Shares CARES-310, Camrelizumab + rivoceranib, Rivoceranib (apatinib), Hepatocellular carcinoma and the tag china.